Relationship of glucose concentrations with PAI-1 and t-PA in subjects with normal glucose tolerance.
OBJECTIVE
To study metabolic risk factors for the development of cardiovascular disease (CVD), including markers of the fibrinolytic system in relation to blood glucose levels in subjects with normal glucose tolerance and fasting blood glucose levels below 5.6 mmol/l.


METHODS
Cross-sectional, community-based study from a primary health-care centre of adult subjects with normal glucose tolerance. Analysis of fasting and 2-h post-load blood glucose concentrations were centralized and related to anthropometric characteristics, metabolic variables, inflammatory markers, and coagulation and fibrinolytic variables.


RESULTS
Increasing fasting blood glucose concentrations within the normal range in subjects with normal glucose tolerance were associated with increasing age, body mass index, and waist circumference, and with increasing concentrations of metabolic risk factors for development of CVD. After adjustment for gender, age, body mass index (BMI), and fasting insulin, levels of plasmin activator inhibitor (PAI-1) and tissue type plasminogen activator (t-PA) increased significantly with increasing levels of fasting glucose within the normal range (P = 0.012 and P < 0.0001, respectively).


CONCLUSIONS
We found risk factors for CVD, specifically key components of the fibrinolytic system, PAI-1 and t-PA, increased with increasing fasting glucose levels even in subjects with normal glucose tolerance. This observation may help to explain the increased risk of CVD with increasing values of fasting glucose in the normal range.
Heldgaard
P E
PE
Ørum Health Centre, Tjele, Denmark. poul.erik@heldgaard.net
Sidelmann
J J
JJ
Hindsberger
C
C
Olivarius
N de F
Nde F
Henriksen
J E
JE
Gram
J
J
D000328:Adult; D001786:Blood Glucose / Q000378:metabolism*; D003430:Cross-Sectional Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications*; D003925:Diabetic Angiopathies / Q000097:blood / Q000209:etiology*; D005215:Fasting / Q000097:blood; D005260:Female; D006801:Humans; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood / Q000150:complications*; D008875:Middle Aged; D010960:Plasminogen Activators / Q000378:metabolism*; D012307:Risk Factors; D010959:Tissue Plasminogen Activator / Q000378:metabolism*
D001786:Blood Glucose; D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator